Stay Updated
For all press requests, please reach out to [email protected].
News and Reports
Washington Post Health Brief: Health Brief: Health care’s December pileup
“Patients need systemic reforms that will lower drug prices, rather than short-term, voluntary agreements whose terms remain secret,” said Merith Basey, CEO of advocacy group Patients For Affordable Drugs. The deals announced on Monday, Basey added, “focus on Medicaid, where steep discounts already exist, and even then, states can choose whether to participate.”
Press Releases
NEW REPORT: How High Prescription Drug Prices Shape the Lives of Hispanic and Latino Families
WASHINGTON, D.C. — Hispanic and Latino patients are delaying treatment, rationing medication, taking on debt, and traveling abroad to purchase prescription drugs because they cannot afford the high prices charged in the United States, according to a new report released today by Patients For Affordable Drugs, We Are Más, and Brown University’s Information Futures Lab. […]
News and Reports
Common Dreams: Trump Pharma Deals Called Distraction From ‘Failed Plan to Lower US Drug Prices’
Like Public Citizen, the advocacy group Patients for Affordable Drugs was critical of the new deals, with CEO Merith Basey pointing out that “for decades, drug companies have been charging Americans at least four times more for brand-name medicines than people in other high-income nations.” “Patients need systemic reforms that will lower drug prices, rather […]
News and Reports
USA Today: Trump touts drug-pricing pacts with these 9 pharma manufacturers
Merith Basey, CEO of Patients for Affordable Drugs, said pharmaceutical companies for decades have charged consumers too much for brand name drugs. She said patients need “systemic reforms that will lower drug prices, not short-term, voluntary agreements whose terms remain secret.” “The deals announced today focus on Medicaid, where steep discounts already exist, and even […]
Press Releases
Patients For Affordable Drugs Reacts to New White House MFN Agreements
WASHINGTON, D.C. — The White House today announced agreements with nine additional pharmaceutical corporations as part of the administration’s Most Favored Nation (MFN) drug pricing strategy. Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB have agreed to provide Medicaid programs access to MFN drug prices on their products. […]